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Abstract
Background: Artemisinin-based combination treatments (ACTs) or intravenous artesunate are used in over 100
countries for uncomplicated or severe falciparum malaria. Although intravenous artesunate may cause delayed
haemolytic anaemia, there is little evaluation of the temporal changes in haematocrit following ACTs.
Methods: Clinical and parasitological parameters were measured before and following treatment of uncomplicated
falciparum malaria in children with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL) over 6-weeks.
Changes in haematocrit were characterized in individual patients based on a haematocrit <30 % or ≥30 %
before and following treatment. Kinetics of the deficit in haematocrit from <30 % until attainment of ≥30 %
were estimated by a non-compartment model.
Results: In 248 of 1180 children eligible for evaluation, common temporal patterns were: no change or increase in
haematocrit from≥ 30 % [50 % of patients], haematocrit >30 % at presentation declining to <30 % within 2 weeks
(early monophasic fall) [19 % of patients], and haematocrit <30 % at presentation increasing to ≥ 30 % [23 %
of patients]. Haematocrit >30 % at presentation declining to <30 %, 3–5 weeks later (late monophasic fall)
occurred in 7 children (3 %). Fall in haematocrit ≥5 units following treatment occurred in 57 children [23 %]
between 14 and 28 days after treatment began. Baseline parasitaemia and proportion with > 100,000μL-1
asexual forms were significantly higher in children with ≥5 units compared to <5 units fall in haematocrit 21
or 28 days after treatment began. Irrespective of pattern, declines in haematocrit deficit from <30 % were
mono-exponential, with similar half-times for AA- and AL-treated children (1.32 d versus 1.14 d). Anaemia half-
time correlated significantly positively with anaemia recovery time in the same patients (r = 0.55, P < 0.0001).
Bland-Altman analysis of 9 or 10 multiples of anaemia half-time and anaemia recovery times showed narrow limit of
agreement with insignificant biases (P = 0.19 or 0.63, respectively).
Conclusions: In uncomplicated falciparum malaria, increases or falls in haematocrit are common following ACTs. Falls
in haematocrit≥ 5 units are common and may or may not result in early or late anaemia. In children who recovered
from acute falciparum malaria-associated anaemia following ACTs, decline in haematocrit deficit is mono-exponential.
Trials registration: Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201508001191898,
7 July 2015 http://www.pactr.org.
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Background
Artemisinin-based combination treatments (ACTs) are
the first line treatments of uncomplicated falciparum
malaria in over 100 countries [1–4] and intravenous
artesunate, considered superior to quinine [5, 6], is
now the recommended treatment for severe falcip-
arum malaria [7]. Recent case reports indicate intra-
venous artesunate may cause delayed haemolytic
anaemia in immunologically naïve patients with severe
falciparum malaria [8–11] and orally administered
ACTs to a lesser extent may cause similar effect even
in uncomplicated infections in children from endemic
areas [11].
Plasmodium falciparum malaria-associated anaemia, is
common in children [12, 13], occurs in 20 – 50 % of
African children with falciparum infections [13–15],
and is thought to be due to destruction of parasitized
and non-parasitized red blood cells and bone marrow
dyserythropoiesis of variable intensity and duration
[16–18]. Two of the hallmarks of sensitive Plasmodium fal-
ciparum infections to ACTs, namely rapid clearance of
asexual parasitaemia and recovery from the symptoms and
signs of the infections [3, 7], are often followed by increases
in haematocrit or haemoglobin in majority of children fol-
lowing recovery from acute infections [12, 13, 19, 20]. A re-
cent study in Nigerian children with uncomplicated
falciparum malaria-associated anaemia at presentation
showed that time elapsing from commencement of
ACTs until resolution of the associated anaemia (an-
aemia recovery time) was approximately 10 days and
was unrelated to age [21].
Despite adoption of ACTs as first line treatments in
many endemic countries, there is little information on
the patterns of change in haematocrit in individual African
children following ACTs of uncomplicated infections.
Such information may not only assist with the com-
munity management of malaria-associated falls in
haematocrit to <30 %, but also with understanding
the extent of falls in haematocrit in the different en-
demic settings, the relationship between falls and
time-course of treatment, and the characteristics of
the children with different pattern of change in haem-
atocrit following ACTs.
In the present study, the temporal patterns of haem-
atocrit after artemisinin-based combination treatments
of uncomplicated falciparum malaria were evaluated in a
group of children resident in an endemic area of south-
western Nigeria. The main aims were to: (i) characterize
the changes in haematocrit with time in the individual
patients, (ii) evaluate the factors contributing to moder-
ate fall (≥5 unit fall from baseline) in haematocrit follow-
ing treatment, and (iii) characterize, kinetically, recovery




The study was a prospective study conducted between
April 2008 and December 2011 in Ibadan, southwestern
Nigeria- an endemic area. It was nested in a larger study
of Plasmodium falciparum malaria-associated anaemia
in children before, during and after artemisinin-based
combination treatments (Pan African Clinical Trial
Registry PACTR201508001188143 & PACTR201508001
191898). The details of the larger study have been re-
ported elsewhere [20, 22, 23]. The study protocols were
approved by the Ministry of Health, Ibadan and the
National Health Research Ethics Committee, Abuja,
Nigeria.
Patients
Briefly, patients were enrolled in the study if they were
aged 6 months–15 years, had symptoms compatible with
acute uncomplicated malaria with Plasmodium falcip-
arum mono-infection ≥2000 μL−1 of blood, no history of
antimalarial drug ingestion in the two weeks prior to en-
rolment, absence of severe malaria [24] and written in-
formed consent given by parents or guardians.
Enrolled patients were randomized to receive artemether-
lumefantrine or artesunate-amodiaquine (co-formulated).
Artemether-lumefantrine (Coartem®, Novatis, Basel,
Switzerland) was given according to body weight: patients
weighing 5–14 kg received one tablet, those weighing
15–24 kg received two tablets, those weighing 25–34 kg
received three tablets, and those weighing >34 kg received
four tablets at presentation (0 hour), 8 hours later and at
24, 36, 48 and 60 hours after the first dose. Each tablet of
artemether-lumefantrine contains 20 mg of artemether
and 120 mg of lumefantrine. Artesunate-amodiaquine
(Coarsucam®, Sanofi Aventis, France) was also given ac-
cording to body weight: patients weighing ≥4.5 to <9 kg
received one tablet, those weighing ≥9 to <18 kg received
one tablet and those weighing ≥18 to <24 kg received one
tablet of the following formulations: 25 mg/67.5 mg,
50 mg/135 mg, 100 mg/270 mg of fixed dose combination
of artesunate/amodiaquine, respectively daily for 3 days.
Children weighing 24–36 kg and >36 kg received 1.5 and
2 tablets, respectively of 100/270 mg of fixed dose com-
bination of artesunate/amodiaquine daily for 3 days.
All drugs were given orally. All doses of artesunate-
amodiaquine were given under direct observed therapy
as were the doses of artemether-lumefantrine given at 0,
8, 24 and 48 hours. Doses of artemether-lumefantrine at
36 and 60 hours were given by parents/guardians of the
children at home and enquiries were made by telephone
calls at the expected times of administration to confirm that
the doses were actually given. Artemether-lumefantrine was
not given with fatty meals.
Sowunmi et al. BMC Infectious Diseases  (2015) 15:454 Page 2 of 14
Thick and thin blood films prepared from finger prick
were stained with Giemsa and examined by light micros-
copy under oil immersion objective lens 1000 x magnifi-
cation by two assessors who did not know the drug
regimen of the patients. A senior member of the study
team reviewed the slides if there was any disagreement
by the two microscopists. In addition, the slide of every
fourth child enrolled in the study was reviewed by the
senior member. Thick and thin blood films obtained
from each child as soon as they came to the clinic on to
blood slides were carefully labeled with the patients’
codes and air-dried before being stained. Follow-up with
clinical and parasitological evaluation was done daily on
days 1–3 and on days 7, 14, 21, 28, 35 and 42.
Parasitaemia, asexual or sexual, in thick films were
estimated by counting asexual and sexual parasites rela-
tive to 500 leukocytes, or 500 asexual or sexual forms
whichever occurred first. From this figure, the parasite
density was calculated assuming a leukocyte count of
6000 μL−1 of blood. A slide was considered parasite
negative if no asexual or sexual parasite was detected
after examination of 200 microscope fields. The cure rates
on days 21 and 28 were adjusted on the basis of the PCR
(polymerase chain reaction) genotyping results of paired
samples of patients with recurrent parasitaemia after day
7 of starting treatment as previously described [20].
Capillary blood collected before treatment and during
follow-up was used to measure hematocrit using a micro-
haematocrit tube and microcentrifuge (Hawksley, Lancing,
UK). Anaemia was defined as a haematocrit <30 % [12, 13].
Anaemia recovery time (in anaemic patients at presenta-
tion) was defined as time elapsing from drug administra-
tion to attainment of a hematocrit value ≥30 % [21, 25] in
patients with anaemia at presentation. In patients who had
early or late monophasic decline in haematocrit which
resulted in anaemia, anaemia recovery time was de-
fined as time from appearance of, to recovery from,
anaemia. Children were also considered to have late fall
in haematocrit attributable to treatment if they had no
concomitant illness during the period of the fall and were
parasite negative by both microscopy and PCR.
Evaluation of temporal changes in haematocrit
following treatment
Haematocrit <30 % and ≥30 % were the reference points
in all classified patterns. Temporal changes in haemato-
crit were classified into the following patterns (Fig. 1).
1. Haematocrit ≥30 % before and following treatment.
2. Haematocrit ≥30 % before treatment, declining to
haematocrit <30 % within 2 weeks of treatment, and
thereafter increasing to ≥30 % by 6 weeks after
treatment (early monophasic fall).
3. Haematocrit ≥30 % before treatment followed by a
decline to haematocrit <30 %, 3–5 weeks following
treatment and then increasing to ≥30 % by 6 weeks
after treatment (late monophasic fall).
4. Haematocrit ≥30 % before treatment, 2 consecutive
haematocrit <30 % within 14 days of treatment,
followed by a rise to haematocrit ≥30 % between 14
and 21 days and a fall to <30 % between day 28–35
(biphasic fall in haematocrit).
5. Haematocrit <30 % before and following treatment
(persistent anaemia).
6. Haematocrit <30 % before treatment followed by an
increase to ≥30 % after treatment (malaria-associated
anaemia at presentation and recovery from anaemia).
7. Haematocrit < 30 % at presentation and till day 14,
followed by a rise to ≥30 % on days 21–28 and a fall
to <30 % on days 35–42.
8. Haematocrit <30 % before treatment, followed by
further falls to ≤25 %, 3–5 weeks following treatment.
9. Unclassifiable.
Kinetics of the disposition of deficit in haematocrit
from 30 %
The kinetics of the disposition of deficit in haematocrit
from 30 %, that is, of anaemia, was as previously de-
scribed [20, 26]. Briefly, in all anaemic patients at enrol-
ment, or when anaemia occurs following treatment,
haematocrit values below 30 % (the lower threshold of
normal) and at follow-up were subtracted from 30 % at
each time of measurement until haematocrit rose to
≥30 %, and the resulting values plotted against time. The
final haematocrit when anaemia resolved was therefore
zero in all patients. However, the final haematocrit at the
time of resolution was assumed to be 0.01 %. The areas
under the curve (AUC) of deficit in haematocrit (from
30 %) versus time were obtained, by the trapezoidal rule
using the computer program Turbo Ken (designed by
Clinical Pharmacology Group, University of Southamp-
ton, United Kingdom) as previously described (20, 26).
AUC was also obtained manually by calculating the aver-
age haematocrit values between two consecutive time
measurements and multiplying it by the time interval
between the measurements, and summing up all the
values, in a manner similar to that for the numerical es-
timation of area under a drug concentration-time curve
[27]. Both measurements by digital computer and man-
ual methods gave the same values. The unit of quantifi-
cation would be %.d, if hematocrit values were used or
g/L.d if hemoglobin values were used. Hematocrit values
may be converted to hemoglobin values by dividing by 3
[28]. The apparent terminal elimination rate constant (λ)
was obtained by least-square regression analysis of the
post-peak log-linear part of the plot of deficit in
hematocrit (from 30 %) versus time, and the apparent
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terminal half-time of anaemia (t1/2(anaemia)) was calcu-
lated from ln/(λ).
Statistical analysis
Data were analyzed using version 6 of Epi-Info software
[29] and the statistical program SPSS for Windows ver-
sion 20.0. [30]. Variables considered in the analysis
were related to the densities of P. falciparum asexual
and sexual forms. Proportions were compared by calcu-
lating χ2 using Yates’ correction, Fisher’s exact or Man-
tel Haenszel tests. Normally distributed, continuous
data were compared by Student’s t test and analysis of
variance (ANOVA). Data not conforming to a normal
distribution were compared by the Mann-Whitney U
tests and the Kruskal Wallis tests. The relationship be-
tween two continuous variables was assessed by Spear-
man’s rank correlation coefficient. Agreement between
pharmacodynamic and pharmacokinetic methods of
evaluating recovery from anaemia was assessed by Bland-
Altman analysis [31]. P-values of <0.05 were taken to indi-
cate significant differences. Data were double entered
serially using patients’ codes and were only analyzed at the
end of the study.
Results
Patients’ characteristics and therapeutic responses
Between April 2008 and December 2011, 1180 pa-
tients were enrolled in prospective studies of the
efficacy of artemisinin-based combination treatments.
All patients, at enrolment and during follow-up, had
haematocrit measured. However, two hundred and
forty eight patients who had haematocrit measured
during the entire period of follow-up were analysed.
Of these, 177 and 71 were treated with artesunate-
amodiaquine and artemether-lumefantrine, respectively.
The clinical characteristics of the patients at enrol-
ment are summarized in Table 1. Forty four per cent
of the patients were aged less than 5 years; hyperpar-
asitaemia (>250,000 μL−1) was found in 8.9 % of the
patients. In general, PCR-corrected cure rates were
similar for both artesunate-amodiaquine and artemether-
lumefantrine (98.3 % [95 % CI 96.1-99.3 %] versus 96.9 %
Fig. 1 Classification of temporal patterns of haematocrit after artemisinin-based combination treatments. HCT, haematocrit
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[95 % CI 93.9-98.2 %] for artesunate-amodiaquine and
artemether-lumefantrine, respectively).
Temporal changes in haematocrit following start of
treatment
Tables 2 and 3 show the distribution of patients and
their characteristics in the different temporal patterns.
Children who were anaemic at presentation (Pattern 6),
were younger, weighed significantly less, had significantly
longer duration of illness and a significantly higher pro-
portion of children who were hyperpyrexia compared to
children without anaemia (Patterns 1 and 2) (Table 2).
However, bodyweight was similar in children in patterns
2 and 6 (by post-hoc comparison). Parasitaemia was
similar in all three temporal patterns. The features of the
other temporal patterns (Patterns 3, 5 and 7) are sum-
marized in Table 3. The features appear similar due to
the small number of patients in each pattern. No patient
could be classified as pattern 4 or 8. Nine patients could
not be classified into any of the patterns described above
(unclassifiable).
In all temporal patterns described (Fig. 2), a prominent
feature is a fall in haematocrit within the first three days
of drug administration–the drug-attributable fall in
haematocrit (DAFH [25]). A late fall in haematocrit
which began after day 14 and persisted beyond 28 days
after treatment began was seen in Patterns 1, 3 & 7
(Fig. 2). The detailed clinical and parasitological char-
acteristics and outcome of treatment of patients with
a late fall in haematocrit resulting in anaemia between
days 21 and 35 are shown in Table 4. At enrolment, 4 of
the 7 patients had parasitaemia >100,000 μL−1, parasit-
emia cleared within 1 day in 6 of 7 children, 3 of 5 chil-
dren treated with artesunate-amodiaquine had total dose
of artesunate >11 mg/kg, and none of the children re-
quired blood transfusion. Also, none of the patients
was older than 9 years. On the whole, virtually all of
these children were anaemic for a period of approxi-
mately 14 days (Additional file 1: Figure S1). The
mean duration of anaemia was 16.0 days (95 % CI
12.8–19.2; range 14–21 days).
Comparison of children with fall in haematocrit ≥5 units
and <5 units following treatment
Because of very few patients with late fall in haemato-
crit (n = 7), the features of children with ≥5 units and
<5 units fall in haematocrit from baseline following
artemisinin-based combination treatments were evalu-
ated. Based on the number of patients evaluated per
visit day, on day 7, 16 of 23 children and 62 of 87 chil-
dren had ≥5 and <5 units fall in haematocrit, respect-
ively, following treatment. The difference between
these proportions was not significant (χ2 = 0.02; P =
0.92). After day 7, overall, 57 of 122 children and 55 of
213 children with ≥5 and <5 units fall in haematocrit, re-
spectively between days 14 and 28 were anaemic (Table 5).
The difference between these proportions was significant
(χ2 = 14.3, P = 0.0001). However, the proportion of chil-
dren who were anaemic on day 14 in the 2 groups, re-
spectively were similar (29 of 52 v 32 of 65, χ2 = 0.3, P =
0.60). On day 21, 20 of 48 children and 18 of 75 children
in the 2 groups, respectively were anaemic (χ2 = 4.2, P =
0.04 by Mantel Haenszel test). On day 28, 8 of 22 and 5 of
73 children (Table 5) in the 2 groups, respectively were
anaemic (χ2 = 10.1, P = 0.0001).
Table 6 shows the clinical and parasitological parame-
ters of the 89 children who had a fall of ≥5 or <5 unit in
haematocrit from baseline on days 21 or 28, or on both
days. Children with ≥5 units fall in haematocrit had sig-
nificantly higher baseline haematocrit, parasitemia and
proportion of children with asexual forms >100,000 μL−1.
However, median doses of artesunate were similar in the
two groups. Similarly, the median doses of artemether,
lumefantrine or amodiaquine were similar in the two
groups. In a univariate analysis (see Additional file 2:
Table T1), a parasitaemia >100,000 μL−1 at enrollment
was significantly associated with ≥5 units fall in
haematocrit from baseline on days 21 or 28 or on
both days.
Table 1 Characteristics of the 248 children enrolled in the study
Value
No. of children 248
Female (%) 117 (47)
aged < 5 years 110
Febrile (> 37.4 °C) 119
Parasitaemia
(> 100,000 μL−1) 71
(> 250,000 μL−1) 22
Anaemia
(< 30 %) 67
(< 15 %) 0
Enlarged liver 50
Enlarged spleen 26
Mean value (range) for
Age (year) 6.3 (0.7–14)
Weight (kg) 18.0 (7–40)
Duration of illness (day) 2.7 (1–7)
Temperature (°C) 38.4 (35–40.9)
Haematocrit (%) 31.9 (18–42)
GMPD (μL−1 of blood) 57,504 (2,000–1,080,200)
Liver enlargement (cm) [n = 50] 2.9 (0.1–8)
Spleen enlargement (cm) [n = 26] 1.5 (0.3–6)
GMPD = geometric mean parasite density
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Kinetics of the disposition of the deficit in haematocrit
from 30 %
(a). Comparison of the kinetics of the disposition of deficit
in haematocrit in children with early (Pattern 2) and late
(Pattern 3) monophasic falls in haematocrit
Forty-eight (31 treated with artesunate-amodiaquine
and 17 treated with artemether-lumefantrine) and 7
(5 treated with artesunate-amodiaquine and 2 treated
with artemether-lumefantrine) children, respectively,
had early and late monophasic falls in haematocrit.
The children from the two groups, respectively had simi-
lar clinical and parasitological parameters at presentation
(Age 5.6 ± 2.7 years [range 2–14] versus 5.6 ± 2.0 years
[range 2–8], P = 0.95; duration of illness 2.8 ± 1.0 d [1–5]
versus 2.5 ± 0.8 d [1–3], P = 0.45; body temperature
38.6 ± 1.0 °C [range 35.0–40.1] versus 38.9 ± 1.3 °C
[range 36.7–40.6], P = 0.38; haematocrit 32.4 ± 2.8 %
[range 30–40] versus 34.1 ± 3.6 % [range 30–40], P = 0.13,
and geometric mean asexual parasite density 59,361 μL−1
blood [range 8,000–1,080,200] versus 67,895 μL−1 blood
[range 14,792–197,308], P = 0.74). The median doses
of the drugs were also similar in the two groups
(data not shown). Time to recover from anaemia
was significantly shorter in children with early than in
those with late monophasic falls in haematocrit (median
11 d [range 2–27; n = 48] versus 14 d [range 14–21;
n = 7], P = 0.003). The mean AUC of deficit in haem-
atocrit versus time was significantly lower in children
with early monophasic fall than in those with late
monophasic fall (mean 14.7 %.d [range 3.7–41.5] ver-
sus 54.1 %.d [range 20.2–116.4], P = 0.002). Declines
of deficit in haematocrit were monoexponential in
both patterns (see Additional file 3: Figure S2). The
half-time of decline was significantly shorter in chil-
dren with early monophasic fall than in those with
late monophasic fall in haematocrit (mean 0.9 ± 0.7 d
Table 2 Clinical, parasitological and other characteristics of patients in different major temporal patterns
aPattern 1 bPattern 2 cPattern 6 ALL eP value
Number (%) 123 (49.6) 48 (19.4) 57 (23) 228 (92)
Gender
M/F 66/57 21/27 33/24 120/108 0.33
Age (year)
Mean (sd) 7.3 (3.6) 5.6 (2.7) 5.3 (2.7) 6.5 (3.3) < 0.0001
Range 0.7–14 2–10 1.2–12.5 0.7–14
Duration of illness (days)
Mean (sd) 2.5 (1.1) 2.8 (1) 3.2 (1.3) 2.7 (1.2) < 0.0001
Range 1–7 1–5 1–7 1–7
Weight (kg)
Mean (sd) 20.2 (7.5) 16.7 (5.3) 16.0 (4.3) 18.4 (6.7) 0.009
Range 7–40 9–31 7–26 7–40
Haematocrit (%)
Mean (sd) 34.7 (2.7) 32.4 (2.8) 26.4 (2.6) 32.3 (4.4) < 0.0001
Range 30–42 30–38 18–29 18–42
Temperature (°C)
Mean (sd) 38.4 (1.1) 38.6 (1) 38.4 (1.2) 38.4 (1.1) 0.60
Range 35–40.9 35–40.1 35.9–40.5 35–40.9
No. with temp.
i. >37.4 °C (%) 97 (79) 42 (88) 43 (75) 182 (80) 0.28
ii. >40.0 °C (%) 8 (7) 1 (2) 14 (25) 23 (10) < 0.0001
Parasitaemia (μL−1)
Geometric Mean 52,037 59,361 64,514 56,468 0.37
Range 2,000-459,000 8,000-1,080,200 2,094-346,153 2,000-1,080,200
No. with ≥100,000 μL−1(%) 34 (27.6) 11 (22.9) 18 (31.6) 63 (27.6) d0.61
aHaematocrit ≥ 30 % before and following treatment
bHaematocrit ≥ 30 % before treatment, two consecutive haematocrit < 30 % within 14 days of treatment, followed by a rise to ≥ 30 % [Early monophasic fall]
cHaematocrit < 30 % before treatment, followed by a rise to ≥ 30 % after treatment [malaria-associated anaemia at presentation and recovery from anaemia]
dChi-square test
eP values quoted are for comparison across all three groups
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[range 0.2–2.1] versus 1.6 ± 0.4 d [range 1.1–2.1], P =
0.003).
(b). Anaemia at presentation followed by recovery (Pattern 6)
The demographic and other characteristics of the 57
children (n = 39 for artesunate-amodiaquine and n = 18
for artemether-lumefantrine) have been summarized in
Table 2. Overall, in all children, mean AUC of deficit in
haematocrit versus time was 74.2 %.day (95 % CI 59.3–
89.1, range 0.7–286.2) and it was similar in anaemic
children treated with artesunate-amodiaquine and
artemether-lumefantrine (mean 72.7 %.day [95 % CI
54.1–91.2, range 0.7–286.2] versus mean 77.3 %.day
[95 % CI 50.1–104.6, range 0.7–224.6], P = 0.77)
(Fig. 3). Overall, in all children, there was mono-
exponential decline of the deficit in haematocrit (see
Additional file 4: Figure S3) with an estimated half-
time (t½) of 1.3 d (95 % CI 1.2 – 1.5, range 0.2–2.5).
Estimated mean t½ were similar in children treated
with artesunate-amodiaquine and artemether-lumefantrine
(mean 1.3 d [95 % CI 1.1–1.5, range 0.2–2.5] versus mean
1.3 d [95 % CI 1.1–1.6, range 0.2–2.1], P = 0.93).
(c) Relationship between half time of decline in haematocrit
deficit and anaemia recovery time
The relationship between the half-time of decline in
haematocrit deficit from 30 % and anaemia recovery
time in the same patients with anaemia at presenta-
tion was evaluated in 57 children. The mean half-
time of decline in haematocrit deficit from 30 % was
1.3 days (95 % CI 1.2–1.5, range 0.2–2.5). The median an-
aemia recovery time was 14 days (range 1–21). There was
a significantly positive correlation between half-time of
decline in haematocrit deficit from 30 % and anaemia re-
covery time (r = 0.55, P < 0.0001, see Additional file 5:
Figure S4). The ratio of anaemia recovery time to half
time of decline in haematocrit in individual patient
was 10.0 (95 % CI 9.0–11.1). Bland-Altman plots of
the anaemia recovery times and multiples of anaemia
half-times are shown in Fig. 4. The limits of agree-
ment between anaemia recovery times and 9 or 10
multiples of anaemia half-times were narrow. At 9
and 10 anaemia half-time, the limits of agreement
were −9.8–12 days and −11–11 days, respectively.
The bias at multiples of 9 or 10 anaemia half-times
was statistically insignificant (P = 0.19 and 0.63, respect-
ively). However, there was a statistically significant bias at
multiples of 7 or 8 anaemia half-times (P < 0.0001 and P =
0.002, respectively).
Discussion
In this study, in keeping with previous reports, the
commonest changes in haematocrit after successful
artemisinin-based combination treatments of uncom-
plicated falciparum infections in children are increases
in haematocrit in non-anaemic (Pattern 1) and an-
aemic (Pattern 6) children at presentation [12, 13, 19,
20, 23, 25, 32]. When combined with children who
had no anaemia – early anaemia – no anaemia pat-
tern (Pattern 2, early monophasic fall in haematocrit),
over 90 % of the children could be classed into one
of these three patterns. Compared to children with
normal haematocrit at presentation and following
treatment (Pattern 1) and those with early monophasic fall
in haematocrit (Pattern 2), children with anaemia – no
anaemia pattern (Pattern 6, acute falciparum malaria-
associated anaemia at presentation and recovery from an-
aemia) were significantly younger and had significantly
longer duration of illness in keeping with previous find-
ings [12, 13, 15]. However, baseline parasitaemia was
Table 3 Clinical, parasitological and other characteristics of
patients in different minor temporal patternsd
aPattern 3 bPattern 5 cPattern 7
Number (%) 7 (2.8) 1 (0.4) 3 (1.2)
Gender
M/F 4/3 0/1 2/1
Age (year)
Mean (sd) 5.6 (2) 2 2.7 (0.3)
Range 2–8 2 2.5–4
Duration of illness (days)
Mean (sd) 2.5 (0.8) 3 2.3 (0.6)
Range 1–3 3 2–3
Weight (kg)
Mean (sd) 17 (3.1) 10 11.7 (2.5)
Range 13–20 10 9–14
Haematocrit (%)
Mean (sd) 34.1 (3.6) 22 27.3 (2.1)
Range 30–40 22 25–29
Temperature (°C)
Mean (sd) 38.9 (1.3) 37.1 38.8
Range 36.7–40.6 37.1 38.8
No. with temp.
>37.4 °C (%) 6 (86) 0 (0) 3 (100)
>40.0 °C (%) 2 (29) 0 (0) 0 (0)
Parasitaemia (μL−1)
Geometric mean 67,985 288,461 65,333
Range 14,792-197,308 288,461 21,220-467,681
No. with >100,000 μL−1 (%) 3 (43) 1 (100) 1 (33)
aHaematocrit≥ 30 % before treatment followed by haematocrit < 30 % 3 – 5 weeks
following treatment, and a rise to≥ 30 % by 6 weeks after treatment
bHaematocrit < 30 % before and following treatment
cHaematocrit < 30 % before treatment, followed by > 30 % by days 21–28, and
thereafter a fall to <30 %, 5 – 6 weeks following treatment
dStatistical comparison not carried out because of very few number of patients
in the three patterns
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similar in all the three patterns, − a finding in anaemia –
no anaemia pattern that is at variance with some reports
showing high parasitaemia is a risk factor for anaemia at
presentation in children with acute falciparum malaria
[12, 13, 15].
Of theoretical interest, for which no child was classi-
fied is: no anaemia at presentation, followed by anaemia,
recovery from anaemia, and a late fall in haematocrit to
anaemia level (Pattern 4). This pattern appears to have
combined features of Pattern 2 and Pattern 3 and may
Fig. 2 Temporal patterns of haematocrit after artemisinin-based combination treatments. Single arrow indicates drug attributable fall, and double
arrows indicate late fall in haematocrit even in patients with normal haematocrit during entire period of follow up (see Pattern 1)
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Total of mg/kg dose of AA Total of mg/kg dose of AL
Artesunate amodiaquine artemether lumefantrine
13 (F, 4.9y) 2010 357,397 40 AA 1 27 (21) 30 14 11.5 31.2 NA NA
20 (M, 4.9y) 2010 197,308 30 AL 1 20 (21) 40 14 NA NA 9.2 55.4
28 (F, 8y) 2010 157,200 37 AA 1 27 (14) 33 14 17.5 30.0 NA NA
45 (M, 5.4y) 2009 34,000 30 AL 2 28 (21) 32 21 NA NA 15 90
93 (F, 7.8y) 2009 35,593 34 AA 1 23 (21) 31 21 7.5 23.0 NA NA
167 (M, 6y) 2009 14,792 34 AA 1 29 (21) 33 14 16.7 51.0 NA NA
200 (M, 2y) 2009 181,000 34 AA 1 28 (14) 33 14 10.5 42.6 NA NA
aPercentage fall in haemaocrit compared to pre-treatment values in descending order of cases are: 40 %, 33 %, 33 %, 32 %,27 %, 18 %, and 15 %, respectively
NA = Not Applicable; AA = artesunate-amodiaquine; AL = artemether-lumefantrine; HCT = Haematocrit, PCT = Parasite clearance time














be considered a variant of both Patterns 2 and 3. It
would appear that the 3 patients included under pattern
7 appeared to have ‘undulating pattern’. We do not have
an explanation for this pattern.
It is noteworthy that a late fall in haematocrit to a
level below normal occurred in 3 % of the children
(Pattern 3, Table 4). Over half of the children with
late fall in haematocrit had high parasitaemia
(>100,000/μL), virtually all their parasitaemias cleared
by 1 day after treatment started and 3 of 5 children treated
with artesunate-amodiaquine had >11 mg/kg of artesu-
nate. With the exception of overt clinical and other la-
boratory manifestations of haemolysis, the features of
these children superficially resemble those of immuno-
logically naïve patients with delayed haemolytic anaemia
following intravenous artesunate treatment of severe
falciparum malaria [8–11]. In some of the children with
late fall in haematocrit who were treated with artemether-
lumefantrine, the dose of artemether was not particularly
high. It is likely that the children who received higher dose
of artesunate were on the lower segment of the dose range
since co-formulated preparations were used. Thus, in un-
complicated falciparum malaria when compared with se-
vere malaria, the late fall in haematocrit to anaemia level
may be associated with subtle clinical or laboratory fea-
tures of haemolysis.
All of the factors associated with late monophasic fall
in haematocrit after artemisinin-based combination
treatments of uncomplicated falciparum malaria are not
known. In order to understand some of these factors, a
comparison of falls in haematocrit from baseline ≥5
units or <5 units after treatment was assessed by com-
paring the features of patients in the 2 groups. Approxi-
mately half of the patients with falls in haematocrit ≥5
units had their falls 21–28 days after treatment began
(see Table 5). In these patients, the ≥5 units fall was as-
sociated with significantly higher baseline parasitaemia,
a significantly higher proportion of patients with a para-
sitemia in excess of 100,000 asexual forms/μL, but not
significantly higher doses of all the combination drugs
compared with children who had <5 units fall in
haematocrit (from baseline) following treatment. These
findings superficially resemble those of the reported
cases of late haemolytic anaemia following intraven-
ous artesunate treatment of severe falciparum malaria
[9, 10]. Since 40 % of the children with falls in haem-
atocrit ≥5 units between 21 and 28 days after treat-
ment began developed late monophasic anaemia as
compared to 16 % of those with <5 units fall in haemato-
crit during the same period, it follows that late fall in
haematocrit from baseline ≥5 units may or may not result
in anaemia. This may explain the relatively low prevalence
of late monophasic anaemia following artemisinin-based
combination treatments in general. In this context, studies
on the risk factors for late monophasic anaemia after
artemisinin-based combination treatments of uncompli-
cated falciparum malaria in children are urgently needed
in this endemic area.
In the area of study, the relatively common occurrence
of the haemoglobinopathies, glucose-6-phosphate de-
hydrogenase deficiency, and intestinal helminth infec-
tions [33–36] may contribute to the background low
haematocrit or even to the early monophasic decline in
haematocrit following treatment but the extent may be
difficult to quantify. However, they are less likely to con-
tribute much to the late monophasic fall in haematocrit.
The anaemia associated with falciparum malaria is
multifactorial and is thought to be due to greater de-
struction of unparasitized red blood cells compared to
parasitized red blood cells, and bone marrow dyserythro-
poiesis of variable intensity and duration [16–18, 37–39].
It is likely that the late monophasic fall in haematocrit
(Pattern 3) following artemisinin-based combination treat-
ments, is due to the late destruction of red blood cells
from which parasites have been removed in the spleen by
pitting-the parasite-negative-red cell surface antigen posi-
tive red cells [40]. These red blood cells are found in the
circulation in large numbers within 24 hours of initiating
treatment with artesunate, but they have shortened sur-
vival time in severe malaria compared with unparasitized
red blood cells [41] and are therefore expected to be
destroyed 3–5 weeks after treatment began [10, 11]. Thus,
Table 5 Fall in haematocrit according to time of follow-up in children treated with artesunate-amodiaquine or artemether-
lumefantrine
Days after start of treatment
Extent of fall 14 Anaemia 21 Anaemia 28 Anaemia 35 Anaemia 42 Anaemia
Yes No Yes No Yes No Yes No Yes No
≥ 5 % fall in haematocrit 29a 23a 20 28 8 14 0 11 1 15
< 5 % fall in haematocrit 32 33 18 57 5 68 5 62 3 61
Total 61 56 38 85 13 82 13 82 4 76
aNumber of children evaluated per visit day
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in patients with high parasitaemia, the fall in haematocrit
in the first few days following artemisinin-based combin-
ation treatments is less than expected were all the parasit-
ized red blood cells to be destroyed [42, 43]. It is also
remotely possible that, in addition to these once infected
red blood cells, apparently non-infected red blood cells
may also be destroyed.
Recent case definition of post-artesunate delayed
haemolytic (PADH) syndrome [44, 45] consists of 10 %
fall in haemoglobin associated with haptoglobin <0.1 g/L
and either an increase in LDH to >390 IL/L or a 10 %
rise >7 days after start of treatment with artesunate in
naïve patients with severe malaria. This syndrome has
been reported in 7 % of African children with severe
Table 6 Clinical, parasitological and other characteristics of patients with falls in haematocrit ≥5 and <5 units on day 21, 28 or both
following treatment with artesunate-amodiaquine or artemether-lumefantrine
≥5 units fall in haematocrita <5 units fall in haematocrit P value
Number 51 38
M/F 27/24 22/16 0.72
Age (year)
Mean (sd) 6.6 (3.1) 6.8 (3.3) 0.73
Range 0.7 – 13.0 2.5–14
No. < 5 years 19 18 0.46
Duration of illness (days)
Mean (sd) 2.6 (1) 2.6 (0.9) 0.96
Range 1–5 1–5
Weight (kg)
Mean (sd) 18.8 (6.7) 19.1 (6.2) 0.82
Range 7–37 11–36
Haematocrit (%)
Mean (sd) 35.9 (3.3) 33.1 (3) < 0.0001
Range 29–42 24–38
Temperature (°C)
Mean (sd) 38.2 (1.1) 38.5 (1.3) 0.26
Range 35.0–40.4 36.0–40.9
No. with temperature
>37.4 °C 39 31 0.68
>40.0 °C 3 5 0.25
Parasitaemia(/μL)
Geometric mean 72,208 44,751 0.026
Range 3,529–501,946 3,749–281,538
No. with parasitaemia
> 100,000/μL 22 6 0.003
> 250,000/μl 5 2 0.42
PCT (day) (sd) 1.1 (0.2) 1.2 (0.4) 0.14
No. with parasitaemia on day 1 3 6 0.15
Median dose (mg/kg)
Artesunate (range) 12.5 (5–40) [n = 43] 11.1 (4.7–18) [n = 24] 0.12
Amodiaquine (range) 33.5 (15.3–76.5) [n = 43] 30.9 (14.3–55.1) [n = 24] 0.18
Artemether (range) 10.7 (9.2–16) [n = 8] 12.4 (7.1–16) [n = 11] 0.78
Lumefantrine (range) 64.3 (55.4–96) [n = 8] 68.6 (42.4–90) [n = 11] 0.78
aSix of the seven children with late fall in haematocrit belong to this group (see also Table 4)
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malaria treated with parenteral artesunate [46]. Although
the seven children with delayed fall in haematocrit in our
series did not meet this strict case definition, it is likely
that the syndrome of delayed fall in haematocrit, not asso-
ciated with severe malaria may occur in children with
uncomplicated falciparum malaria following artemisinin-
based combination treatments. In this context, the recent
introduction and use of dihydroartemisinin-piperaquine
(DHP) for the treatment of uncomplicated falciparum
malaria in endemic areas of Africa would require close
monitoring for the syndrome of delayed fall in haemato-
crit or heamoglobin as reported in 3 % of children follow-
ing artemisinin-based combination treatments in this
endemic area. This would be necessary since artesunate
and artemether are metabolized to dihydroartemisinin. In
addition, monitoring may help define the risk factors for
artemisinin-related late falls in haematocrit following
treatment of uncomplicated falciparum malaria in children.
Declines in haematocrit deficit from 30 % (that is, re-
covery from anaemia) were mono-exponential irrespect-
ive of whether the deficit was early or late, suggesting
that using a non-compartment model, recovery from ap-
parently uncomplicated falciparum malaria-associated
anaemia is a first order process. In this and other con-
texts, early fall in haematocrit to <30 % differs from late
Fig. 3 Distribution of individual area under curve (AUC) of deficit in
haematocrit from 30 % in children with anaemia at presentation (Pattern
6), after treatment of falciparum infections with artemether-lumefantrine
(AL) or artesunate-amodiaquine (AA). ALL; all children. Horizontal bars
indicate mean AUC
Fig. 4 Bland-Altman plots of anaemia recovery times and multiples [7 a 8 (b), 9 (c) and 10 (d)] of anaemia half-times. Biases were 3.62, 2.29, 0.96
and −0.36 for plots A, B, C and D; P < 0.0001, P = 0.002, 0.19 and 0.63, respectively. The mean values ± 1.96 standard deviation (SD) of the differences
are shown
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fall to <30 % by its shorter half-time of anaemia. These
two patterns also differ in their anaemia recovery times
and AUC of deficit in haematocrit versus time. These
differences suggest that, on the whole, the late monopha-
sic anaemia may be more ‘intense’ than the early mono-
phasic anaemia. A further application of pharmacokinetic
principles should permit treatment of the increases in
haematocrit associated with artemisinin-based combin-
ation treatments of uncomplicated falciparum malaria.
In this study, a pharmacodynamic-pharmacokinetic ap-
proach was used to quantify the time to resolve uncompli-
cated malaria-associated anaemia following artemisinin-
based combination treatments. The approach showed the
following: (i). Anaemia half-time correlated significantly
with anaemia recovery time in the same patient. (ii).
Greater than 8 multiples of anaemia half-times showed an
insignificant bias when a Bland-Altman analysis was used.
Thus, confirming that >8 multiples of anaemia half-times
can be used interchangeably with anaemia recovery
time for the evaluation of recovery from uncomplicated
malaria-associated anaemia following artemisinin-based
combination treatments. Therefore, the agreement be-
tween 9 or 10 multiples of anaemia half-times and an-
aemia recovery time was not unexpected since it takes
9 or 10 half-times for 99.6 or 99.9 % completion of an
elimination process in a simple one compartment phar-
macokinetic model. The ratio of anaemia recovery time
to anaemia half-time of approximately 10 in the pa-
tients also indirectly support the model.
There are limitations of the present study. First, al-
though the clinical and parasitolgical features of children
with fall in haematocrit to anaemia level on days 21–42
after commencement of treatment were characterised,
the nature of the anaemia was not fully characterized
(i.e. whether it was haemolytic or not in nature). Second,
in the children with late fall in haematocrit to anaemia
level, quantification of once-infected and infected red
blood cells and the disposition of these red cells during
the course of follow-up was not evaluated. Third, The
precise contribution of the background causes of anaemia
in children from the endemic area (such as the haemoglo-
binopathies, malnutrition and intestinal helminth infec-
tions) to the time-course of haematocrit was not assessed.
Conclusions
Increases in haematocrit are common following
artemisinin-based combination treatments of uncompli-
cated falciparum malaria, but falls in haematocrit from
baseline ≥5 units are also relatively common and may or
may not result in early or late anaemia. In children who
recovered from acute falciparum malaria-associated an-
aemia following artemisinin-based combination treatments,
declines in haematocrit deficit (from 30 %, the lower thresh-
old of normal) are mono-exponential.
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